查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1733328

全球醫療奈米技術（奈米醫學）市場規模（按模式、適應症、應用、區域範圍和預測）

Global Healthcare Nanotechnology (Nanomedicine) Market Size By Modality (Treatment, Diagnostics), By Indication (Clinical oncology, Infectious diseases), By Application (Drug Delivery, Regenerative medicine), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

醫療奈米技術（奈米醫學）市場規模與預測

2024 年醫療奈米技術（奈米醫學）市場規模價值 2,203.4 億美元，預計到 2032 年將達到 5,529.3 億美元，2026 年至 2032 年的複合年成長率為 13.14%。

隨著法律規範的完善，全球醫療奈米技術（奈米醫學）市場正在成長。開創性的技術發展和不斷增加的研究投入將推動市場擴張。 COVID-19 對奈米醫學領域產生了相對正面的影響。這是因為奈米藥物在治療癌症類疾病的需求迅速成長。此外，由於各領域的奈米醫學研發活動的活性化，市場參與企業在材料和資源方面的支出也在增加。全球醫療奈米技術（奈米醫學）市場報告對市場進行了全面評估。它對關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

定義全球醫療奈米技術（奈米醫學）市場

奈米技術是21世紀最有前途的技術之一。奈米技術是指技術發展發生在 0.1 至 100 奈米尺度上時所使用的術語。奈米醫學通常是奈米技術的一個分支，涉及分子層面的醫學發展，用於疾病的診斷、預防、治療，甚至組織和器官的再生。奈米技術是21世紀最有前途的技術之一。奈米技術是指技術發展發生在 0.1 至 100 奈米尺度上時所使用的術語。奈米醫學通常是奈米技術的一個分支，涉及在分子層面上開發醫學治療方法，以診斷、預防、治療疾病，甚至組織和器官的再生。

維持和改善人類健康是幫助實現這一目標的一種方式。奈米醫學為各種危及生命的疾病提供了強力的解決方案，例如整形外科問題、血液、肺部、癌症、帕金森氏阿茲海默症、阿茲海默症、糖尿病以及與神經和循環系統相關的疾病。這些是具有可程式設計特性的多功能藥物，將有助於利用奈米設備和奈米粒子在分子層面監測、建構、修復和控制生物系統。它由多種技術支持，包括樹狀聚合物、膠束、結晶、富勒烯、病毒體奈米顆粒、奈米孔、脂質體、奈米棒、乳化、量子點和奈米機器人。

奈米醫學可能是治療癌症的一種有希望的途徑。這一日益成長的醫學研究領域通常是由尋找針對各種疾病（包括癌症）的更個人化的治療方法的願望所驅動。奈米醫學的優點在於擁有奈米級材料的特性，因此有望開發出比標準治療方法更有效、副作用更少的創新藥物。因此，對技術進步的需求以增強疾病的診斷、治療和預防已被證明是醫療奈米技術（奈米醫學）市場的主要驅動力。就癌症而言，奈米醫學為目前的癌症診斷和治療方法帶來了有希望的轉變。

全球醫療奈米技術（奈米醫學）市場概覽

奈米醫學有可能徹底改變和革新當前疾病的檢測、診斷和治療方式。隨著藥物傳輸等創新技術的出現，奈米醫學提供了多種優勢，預計將顯著推動全球醫療奈米技術（奈米醫學）市場的發展。政府資金和支持的增加將導致市場需求增加，而安全且具有成本效益的治療方法將支持市場成長。

新興經濟體中奈米藥物許可的增加和醫療設施的成長有助於為市場成長創造充足的機會。預計與疾病早期診斷、預防干涉以及慢性和急性疾病預防相關的應用等技術進步將推動該市場的成長。奈米技術透過在奈米尺度上將較大的結構和化學物質微型化，正在迅速徹底改變藥物輸送，從而影響該技術的採用。

由於政府機構的資金增加，奈米機器人技術有望發展，這將激發市場潛力。預計由奈米分子和相關技術驅動的產品線將為市場帶來潛在的成長途徑。 DNA摺紙在醫療保健應用中的使用將推動全球醫療保健奈米技術（奈米醫學）市場的成長。然而，漫長的核准過程和與奈米醫學相關的風險（環境影響）限制了市場的成長。

目錄

第1章 全球醫療奈米技術（奈米醫學）市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章 全球醫療奈米技術（奈米醫學）市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球醫療保健領域奈米技術（奈米醫學）市場（按方式）

  • 概述
  • 治療
  • 診斷

第6章 全球醫療奈米技術（奈米醫學）市場（按適應症）

  • 概述
  • 臨床腫瘤學
  • 感染疾病
  • 臨床心臟病學
  • 整形外科
  • 神經病學
  • 泌尿系統
  • 眼科
  • 免疫學
  • 其他

7. 全球醫療奈米技術（奈米醫學）市場（按應用）

  • 概述
  • 藥物輸送
  • 再生醫學
  • 植入
  • 診斷
  • 影像學
  • 疫苗
  • 其他

8. 全球醫療奈米技術（奈米醫學）市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東和非洲

9. 全球醫療奈米技術（奈米醫學）市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第10章 公司簡介

  • Sanofi SA
  • Abbott
  • Pfizer Inc.
  • CombiMatrix Corporation
  • GE Healthcare
  • Celgene Corporation
  • Johnson & Johnson Services, Inc.
  • Luminex Corporation
  • Merck & Company, Inc.
  • Nanosphere
  • Nanosphere, Inc.
  • Bristol-Myers Squibb
  • Leadient BioSciences Inc.
  • Teva Pharmaceutical Industries Ltd
  • Mallinckrodt plc.

第11章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第12章 附錄

  • 相關調查
簡介目錄
Product Code: 63885

Healthcare Nanotechnology (Nanomedicine) Market Size And Forecast

Healthcare Nanotechnology (Nanomedicine) Market size was valued at USD 220.34 Billion in 2024 and is projected to reach USD 552.93 Billion by 2032, growing at a CAGR of 13.14% from 2026 to 2032.

The Global Healthcare Nanotechnology (Nanomedicine) Market is growing as the regulatory framework improves. Growth in technological developments, as well as an increase in research investment, will drive market expansion. COVID-19 has had a relatively good impact on the nanomedicine sector. This was attributable to a surge in the need for nanomedicines used to treat cancer-like disorders. Furthermore, market participants have seen a growth in spending on materials and resources as a result of an increase in nanomedicine R&D activities in all areas. The Global Healthcare Nanotechnology (Nanomedicine) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Healthcare Nanotechnology (Nanomedicine) Market Definition

Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs. Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs.

Preserving and improving human health helps in doing so. For various life-threatening diseases like orthopedic problems, diseases related to blood, lungs, cancer, Parkinson's, Alzheimer's, diabetes, neurological, and cardiovascular system Nanomedicine offers a strong solution. These are multifunctional drugs with programmable properties which help in finding the applications such as monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. Development of a replacement nanomedicine takes several years which is supported by various technologies like dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

Nanomedicine may be a promising mode of cancer treatment. This growing field of medical research is often wont to discover a better-personalized treatment for a good range of diseases, including cancer. As nanomedicine promises to develop innovative drugs which have greater efficacy and lesser side effects than standard therapies because of its benefits as it has the properties of matter at the nanoscale. The necessity for technological advancements to reinforce disease diagnosis, treatment, and prevention is thus found to be the main driver for the Healthcare Nanotechnology (Nanomedicine) Market. Within the case of cancers, nanomedicine offers promising changes from the present methods of diagnosing and treating cancer.

Global Healthcare Nanotechnology (Nanomedicine) Market Overview

Nanomedicines have the potential which can fully change or revolutionalize the current scenario of detection of disease, diagnosis, and treatment methods. With the emergence of innovative technologies such as drug delivery, and also there are several benefits of nanomedicine that will significantly boost the Global Healthcare Nanotechnology (Nanomedicine) Market. Rising government funding and support will lead to an increase in demand for the market as well as its safe and cost-effective therapies will support the market growth.

The increasing out-licensing of nano drugs and the growth of healthcare facilities in emerging economies help in creating an ample amount of opportunities for market growth. Technological advancements including relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic also as acute disorders are expected to bolster growth in this market. Nanotechnology involves The miniaturization of larger structures and chemicals at a nanometric scale involves Nanotechnology rapidly revolutionized drug administration, thus influencing the adoption of the technology.

Expected developments in nanorobotics due to the increase in funding from the govt organizations are expected to induce potential in the market. The potential pipeline of products supported by the nano molecules and associated technologies is anticipated to drive the market with potential avenues of growth. Utilization of DNA origami for healthcare applications driving the growth of the Global Healthcare Nanotechnology (Nanomedicine) Market. However, the long approval process and risks related to nanomedicine (environmental impacts) restrain the market growth.

Global Healthcare Nanotechnology (Nanomedicine) Market Segmentation Analysis

The Global Healthcare Nanotechnology (Nanomedicine) Market is segmented on the basis of Modality, Indication, Application, And Geography.

Healthcare Nanotechnology (Nanomedicine) Market, By Modality

  • Treatment
  • Diagnostics

Based on Disease, The market is bifurcated into Treatment and Diagnostics. The Treatment segment holds the largest market share among the others and is anticipated to stay dominant during the projected timeline, owing to technological breakthroughs in nanomedicines, increased nanomedicine adoption, rising chronic disease incidence rates, and an increase in the number of advanced and effective product launches.

Healthcare Nanotechnology (Nanomedicine) Market, By Indication

  • Clinical oncology
  • Infectious diseases
  • Clinical cardiology
  • Orthopedics
  • Neurology
  • Urology
  • Ophthalmology
  • Immunology
  • Others

Based on Application, The market is bifurcated into Clinical oncology, Infectious diseases, Clinical cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology, and Others. The Clinical oncology category was the largest category contributing to the growing market and is expected to maintain its dominance during the projected timeline, owing to an increase in the number of oncology disorders and rising disposable income. In the subject of oncology, nanomedicine provides intriguing alternatives to current cancer treatment and diagnosis approaches. The use of nano-based cancer medicines and diagnostics has made significant progress, and numerous new breakthroughs are currently in the works. Nanobiotix, a clinical-stage nanomedicine company, received CE approval in April 2019 for Hensify (NBTXR3), which is an aqueous suspension of crystalline hafnium oxide or HfO2 nanoparticles intended for injection directly into the tumor prior to a patient's first classic radiation therapy treatment of advanced soft tissue sarcoma.

Healthcare Nanotechnology (Nanomedicine) Market, By Application

  • Drug delivery
  • Regenerative medicine
  • Implants
  • Diagnostic
  • Imaging
  • Vaccines
  • Others

Based on Application, The market is bifurcated into Drug Delivery, Regenerative medicine, Implants, Diagnostic, Imaging, Vaccines, and Others. The Drug delivery sector was the largest contributor to the international market and is expected to persist dominant throughout the projected period, owing to a rise in the frequency of diseases like cancer and the COVID-19 virus, as well as a rise in awareness of the applications of nanomedicines.

Healthcare Nanotechnology (Nanomedicine) Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Regional Analysis, The Global Healthcare Nanotechnology (Nanomedicine) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounts for the maximum market share in this segment. The primary drivers driving market growth in the United States include technology improvements along with applicable applications in early illness detection, preventative intervention, and prevention of chronic and acute disorders, which are likely to drive market expansion. According to the CDC, heart disease accounted for one in every four fatalities in the United States in 2021. Coronary heart disease is the largest cause of death due to cardiac disease in the United States, accounting for 360,900 fatalities, and is followed by stroke (805,000). This high burden may result in a large need for particular therapeutic nano vectors, nanostructured stents, and tissue regeneration implants.
  • Furthermore, various R&D efforts on nanotechnology-based medications and diagnostics are underway in the country, which may fuel market expansion. For instance, in January 2020, Stanford University researchers produced a medication coated with nanoparticles that slows the progression of atherosclerosis in rats by lowering plaque deposition in their arteries without generating negative side effects. However, Asia-Pacific is predicted to develop at the fastest rate over the forecast period. Furthermore, Japan and China are projected to grow at a rapid CAGR in the Asia-Pacific nanomedicine market, owing to improvements in healthcare infrastructure, an increase in the number of health facilities coupled with smart instruments, the development of the R&D sector, an increase in healthcare reforms, and adoption of advanced technologies of nanomedicines.

Key Players

The "Global Healthcare Nanotechnology (Nanomedicine) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sanofi SA, Abbott, Pfizer Inc., CombiMatrix Corporation, GE Healthcare, Celgene Corporation, Johnson & Johnson Services, Inc., Luminex Corporation, Merck & Company, Inc., Nanosphere, Inc., Bristol-Myers Squibb, Leadient BioSciences Inc., Teva Pharmaceutical Industries Ltd, Mallinckrodt plc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • January 2022 - NaNotics LLC has formed a research partnership with the Mayo Clinic to create a NaNot which addresses the soluble form of PD-LI, a tumor-generated immunological inhibitor.
  • December 2021 - Acura NanoMedicine Inc has announced the development of a nanotechnology-based approach to reduce medication resistance and revitalize cancer treatments.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY MODALITY

  • 5.1 Overview
  • 5.2 Treatment
  • 5.3 Diagnostics

6 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY INDICATION

  • 6.1 Overview
  • 6.2 Clinical oncology
  • 6.3 Infectious diseases
  • 6.4 Clinical cardiology
  • 6.5 Orthopedics
  • 6.6 Neurology
  • 6.7 Urology
  • 6.8 Ophthalmology
  • 6.9 Immunology
  • 6.10 Others

7 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Drug delivery
  • 7.3 Regenerative medicine
  • 7.4 Implants
  • 7.5 Diagnostic
  • 7.6 Imaging
  • 7.7 Vaccines
  • 7.8 Others

8 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL HEALTHCARE NANOTECHNOLOGY (NANOMEDICINE) MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Sanofi SA
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Abbott
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Pfizer Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 CombiMatrix Corporation
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 GE Healthcare
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Celgene Corporation
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Johnson & Johnson Services, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Luminex Corporation
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Merck & Company, Inc.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Nanosphere
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 Nanosphere, Inc.
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Bristol-Myers Squibb
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.12 Leadient BioSciences Inc.
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.13 Teva Pharmaceutical Industries Ltd
    • 10.13.1 Overview
    • 10.13.2 Financial Performance
    • 10.13.3 Product Outlook
    • 10.13.4 Key Developments
  • 10.14 Mallinckrodt plc.
    • 10.14.1 Overview
    • 10.14.2 Financial Performance
    • 10.14.3 Product Outlook
    • 10.14.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research